On November 8, Sansure and KHB signed the Letter of Intent for Investment Framework, to establish cooperation in chemiluminescence immunization subdivision to draw on each other’s strengths and achieve win-win results. According to the agreement, Sansure and KHB jointly invest 50 million yuan to establish a joint venture company “Sansure Immunotech” (proposed), with each side holding 50% of the equity. […]

On October 10, Sansure Biotech Inc. won the Medical Innovation Award in the G20 Innovation Alliance Forum held in Sorrento, Italy, making it the only Chinese company receiving this honor. This first ever event in the history of G20 was hosted by the rotating presidency Italy this time, and it was dedicated to sharing ideas and innovative solutions in response […]

According to the agreement, Sansure will work closely with PowerChina International against the backdrop of the grim and complex COVID-19 outbreak overseas. The two parties will exchange experience, resources and reference cases, actively explore and enhance technical support for nucleic acid testing equipment, customer service and joint promotion. This cooperation will help ensure equipment availability and bio-safety, and strengthen protection […]

On August 1st, the much-anticipated Top 100 Pharmaceutical Enterprises in China for 2020 was officially released at the 38th China Pharmaceutical Industry Information Annual Conference 2021, which was organized by the China National Pharmaceutical Industry Information Center. Sinopharm, Yangtze River Pharmaceutical Group and Guangzhou Pharmaceutical Holdings were ranked top three while Sansure Biotech, ranked 59th, is the only biomedical company […]

Sansure Statement on the effectiveness of nucleic acid test kits for the SARS-CoV-2 variants detection